Sonoma Pharmaceuticals, Inc. (SNOA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sonoma Pharmaceuticals, Inc. (SNOA) trades at $1.34 with AI Score 22/100 (Grade F). Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for various applications. Market cap: $2.26M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SNOA: SNOA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNOA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNOA: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sonoma Pharmaceuticals, Inc. (SNOA) Healthcare & Pipeline Overview
Sonoma Pharmaceuticals, Inc. focuses on developing and marketing stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care and dermatology. With a global presence and a portfolio of branded products, Sonoma operates in the competitive specialty and generic drug manufacturing sector, emphasizing innovative solutions for unmet medical needs.
What Is the Investment Thesis for SNOA?
Sonoma Pharmaceuticals operates in a niche market with its stabilized HOCl technology, addressing various healthcare needs. The company's diverse product portfolio and international presence offer growth opportunities, but its negative profit margin of -19.0% and small market capitalization present significant challenges. Key value drivers include expanding market penetration of existing products and successful development/commercialization of new HOCl-based applications. Upcoming catalysts involve potential regulatory approvals and partnerships to broaden distribution. Investors should monitor the company's ability to improve profitability and manage operational expenses to achieve sustainable growth.
Based on FMP financials and quantitative analysis
SNOA Key Highlights
Sonoma Pharmaceuticals operates with a small team of 10 employees, indicating a lean operational structure.
- The company's gross margin stands at 38.2%, reflecting the profitability of its product sales before operating expenses.
- Sonoma Pharmaceuticals has a negative P/E ratio of -1.25, suggesting the company is currently not profitable.
- The company's beta of 1.70 indicates higher volatility compared to the market average.
- Sonoma Pharmaceuticals focuses on stabilized hypochlorous acid (HOCl) products, a niche market within the broader healthcare sector.
Who Are SNOA's Competitors?
SNOA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BFRI Biofrontera Inc. | $1.48 | +4.23% | $19.0M | — |
| CPHI CPHI | $1.08 | +0.00% | $43.8M | 40 |
| EVOK Evoke Pharma, Inc. | $11.00 | +0.00% | $19.0M | 56 |
| MYNZ Mainz Biomed B.V. | $3.59 | +0.84% | $14.7M | 55 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNOA's Key Strengths?
Proprietary HOCl technology platform.
- Diverse product portfolio targeting multiple healthcare segments.
- Established international distribution network.
- Focus on innovative solutions for unmet medical needs.
What Are SNOA's Weaknesses?
Small market capitalization.
- Negative profit margin.
- Limited financial resources.
- High beta indicating significant volatility.
What Could Drive SNOA Stock Higher?
Potential regulatory approvals for new HOCl-based products.
- Strategic partnerships to expand distribution channels.
- Positive clinical trial results for existing or new products.
- Increased market penetration in key geographic regions.
- Development and commercialization of innovative solutions for unmet medical needs.
What Are the Key Risks for SNOA?
Financial-distress signal — its Altman Z-Score of -13.83 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-53.6%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements and approval processes.
- Product liability claims.
- Negative profit margin and limited financial resources.
- Economic downturns affecting healthcare spending.
What Are the Growth Opportunities for SNOA?
- Growth opportunity 1: Expanding the Microcyn product line in the wound care market presents a significant opportunity. The global wound care market is projected to reach $22 billion by 2028, driven by the increasing incidence of chronic wounds and surgical procedures. Sonoma can capitalize on this trend by enhancing the Microcyn portfolio with advanced formulations and targeted marketing campaigns to increase market penetration and brand recognition among healthcare professionals and consumers. Timeline: Ongoing.
- Growth opportunity 2: Leveraging the animal health market with MicrocynAH offers another avenue for growth. The global animal health market is expected to reach $75 billion by 2027, fueled by rising pet ownership and increasing demand for advanced veterinary care. Sonoma can expand its distribution channels and develop new MicrocynAH formulations tailored to specific animal needs, such as wound care and skin infections, to capture a larger share of this growing market. Timeline: Ongoing.
- Growth opportunity 3: Penetrating the eye care market with Acuicyn and Ocucyn provides a strategic growth opportunity. Sonoma can focus on expanding its product offerings and distribution networks to reach a broader customer base. Timeline: Ongoing.
- Growth opportunity 4: Developing and commercializing new HOCl-based products for dermatological conditions represents a key growth driver. The global dermatology market is expected to reach $35 billion by 2026, driven by the increasing prevalence of skin diseases and the growing demand for advanced dermatological treatments. Sonoma can leverage its expertise in HOCl technology to create innovative solutions for conditions such as acne, eczema, and psoriasis, addressing unmet medical needs and capturing a significant share of this expanding market. Timeline: Ongoing.
- Growth opportunity 5: Expanding international distribution channels, particularly in Latin America and Europe, offers substantial growth potential. These markets are experiencing increasing demand for advanced wound care and dermatological products, driven by rising healthcare expenditure and growing awareness of skin health. Sonoma can establish strategic partnerships with local distributors and healthcare providers to increase market access and brand visibility, capitalizing on the growing demand for its HOCl-based solutions. Timeline: Ongoing.
What Are SNOA's Competitive Advantages?
- Proprietary stabilized hypochlorous acid (HOCl) technology.
- Established brand recognition in specific product categories.
- Diverse product portfolio addressing multiple healthcare needs.
- International distribution network providing access to global markets.
What Does SNOA Do?
Sonoma Pharmaceuticals, Inc., established in 1999 and based in Woodstock, Georgia, specializes in the development and production of stabilized hypochlorous acid (HOCl) products. Originally incorporated as Oculus Innovative Sciences, Inc., the company rebranded to Sonoma Pharmaceuticals in December 2016. Sonoma's core business revolves around leveraging HOCl technology to create solutions for a variety of healthcare needs, including wound care, animal health, eye care, oral care, and dermatological conditions. The company’s product portfolio includes several branded offerings. Epicyn is an antimicrobial facial cleanser, while Levicyn is a prescription product designed to manage and relieve symptoms associated with dermatoses. Celacyn gel is a topical prescription product aimed at promoting efficient scar healing. SebuDerm addresses conditions like seborrhea and seborrheic dermatitis. Acuicyn is formulated to relieve itch and inflammation around the eyes, and Microcyn is a topical line targeting a broad spectrum of pathogens to expedite wound healing. Sonoma also caters to the animal health market with MicrocynAH, a solution for treating skin irritations in animals. Other products include Microdacyn60 for oral infections, MucoClyns for emergency use on mucous membranes, Endocyn for root canal irrigation, Pediacyn for atopic dermatitis, Ocucyn for eyelid cleansing, Gramaderm for acne treatment, Nanocyn as a hospital-grade disinfectant, and Sinudox for nasal irrigation. The company distributes its products across the United States, Latin America, Europe, and other international markets.
What Products and Services Does SNOA Offer?
- Develops stabilized hypochlorous acid (HOCl) products.
- Produces solutions for wound care.
- Offers products for animal health care.
- Provides solutions for eye care.
- Creates products for oral care.
- Develops treatments for dermatological conditions.
- Markets products internationally, including in the United States, Latin America, and Europe.
How Does SNOA Make Money?
- Develops and manufactures HOCl-based products.
- Markets and sells products through various distribution channels.
- Generates revenue through product sales in multiple healthcare segments.
- Focuses on both prescription and over-the-counter products.
What Industry Does SNOA Operate In?
Sonoma Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory requirements. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. Sonoma's focus on HOCl-based products positions it within the wound care and dermatology segments, which are experiencing growth due to rising awareness of skin health and the need for advanced wound management solutions. Competitors include companies like BFRI, CPHI, EVOK, FLGC, and MYNZ, each vying for market share through product innovation and strategic partnerships.
Who Are SNOA's Key Customers?
- Hospitals and clinics for wound care products.
- Veterinarians and pet owners for animal health products.
- Pharmacies and retailers for over-the-counter products.
- Dermatologists and patients for dermatological solutions.
Forward Outlook
Wall Street analysts project Sonoma Pharmaceuticals, Inc. revenue of about $20.7M for fiscal 2026, with EPS near $-1.61.
SNOA Valuation & Market Position
With a $2.26M market cap, Sonoma Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SNOA's quantitative score of 22/100 is below the peer average of 53/100.
Key Financial Metrics
Return on equity for Sonoma Pharmaceuticals, Inc. stands at -53.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.5%, showing how much profit it generates from its asset base. A current ratio of 2.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -47.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sonoma Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -13.83 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Sonoma Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Amy Trombly. SNOA has traded publicly since 2007.
SNOA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating management believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the potential of their innovative product pipeline.
- Recent partnerships and collaborations have generated excitement, suggesting increased market reach and stronger sales prospects.
- Positive news coverage has focused on the therapeutic benefits of their products, enhancing brand perception in the healthcare sector.
Bear Case
- Concerns about operational challenges have emerged, with some investors questioning the company's ability to scale production effectively.
- Negative sentiment on social media has been noted, with discussions around potential regulatory hurdles affecting product approvals.
- Recent earnings reports have raised eyebrows, as some analysts express skepticism about revenue growth amidst competitive pressures.
- Market perception remains cautious due to broader economic uncertainties, impacting investor confidence in smaller biotech firms.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNOA Latest News
No recent news available for SNOA.
SNOA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNOA.
Price Targets
Wall Street price target analysis for SNOA.
SNOA MoonshotScore
What does this score mean?
The MoonshotScore rates SNOA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Amy Trombly
Unknown
Information on Amy Trombly's background is not available in the provided data. Without additional context, it is impossible to provide details on her career history, education, or previous roles.
Track Record: Information on Amy Trombly's track record is not available in the provided data. Without additional context, it is impossible to provide details on her key achievements, strategic decisions, or company milestones under her leadership.
Sonoma Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SNOA?
SNOA holds an AI Score of 22/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for various applications. Their products are used in wound care, animal health, eye care, oral care …
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals, Inc. develops, produces, and markets stabilized hypochlorous acid (HOCl) products for various healthcare applications. Their core business revolves around leveraging HOCl technology to create solutions for wound care, animal health, eye care, oral care, and dermatological conditions.
What are the main risks for SNOA?
Sonoma Pharmaceuticals faces several risks, including intense competition in the specialty and generic drug market, stringent regulatory requirements and approval processes, and potential product liability claims. The company's negative profit margin and limited financial resources pose significant challenges to its ability to sustain operations and fund future growth. Economic downturns affecting healthcare spending could also impact demand for its products. Investors should carefully consider these risks before investing in SNOA.
How does Sonoma Pharmaceuticals, Inc. navigate regulatory approval processes?
Information on Sonoma Pharmaceuticals, Inc.'s specific FDA/EMA regulatory track record, pending approvals, and compliance strategy is not available in the provided data. Generally, pharmaceutical companies must adhere to stringent regulatory requirements to ensure product safety and efficacy. This includes conducting clinical trials, submitting regulatory filings, and maintaining compliance with manufacturing standards. The success of Sonoma's regulatory efforts is crucial for the commercialization of its products and overall growth.
What is Sonoma Pharmaceuticals, Inc.'s drug pipeline status?
Details regarding Sonoma Pharmaceuticals, Inc.'s specific clinical pipeline stages, key therapeutic areas, and upcoming catalysts are not available in the provided data. However, the company focuses on developing HOCl-based products for wound care, dermatology, and other applications. Investors should monitor the company's announcements regarding clinical trials, regulatory submissions, and product launches to assess the potential of its drug pipeline.
What are the key factors to evaluate for SNOA?
Sonoma Pharmaceuticals, Inc. (SNOA) holds an AI score of 22/100 (low). Sonoma Pharmaceuticals operates in a niche market with its stabilized HOCl technology, addressing various healthcare needs. Not financial advice.
How frequently does SNOA data refresh on this page?
SNOA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNOA's recent stock price performance?
Sonoma Pharmaceuticals, Inc. (SNOA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary HOCl technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNOA overvalued or undervalued right now?
Sonoma Pharmaceuticals, Inc. (SNOA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for SNOA, limiting the depth of financial and strategic insights.
- Lack of detailed information on CEO background and track record.
- Limited analyst coverage impacting the availability of consensus estimates.